HEALTH CARE POLICY AND LAW

Pharmaceutical Company Payments to Executive Board Members of Professional Medical Associations in Japan
Physicians often receive payments from pharmaceutical companies for purposes that include speaking and consulting. [1] [2] [3] The Japan Pharmaceutical Manufacturers Association includes most companies that manufacture brand name drugs. In 2015, its members accounted for 80.8% of total pharmaceutical sales in Japan. 4 In 2011, the association issued transparency guidelines, which call for disclosure of all payments to physicians, including fees for speaking, writing, and consulting as well as research funding, donations, meals, and other gifts. 5 At present, only payments for speaking, writing, and consulting have been published with individual names and affiliations. Since 2013, annual payment data have been published on each company's website. 5 Compared with Open Payments 6 data in the United States, these disclosures are often unclear and inconsistent: the disclosure format varies between companies, and the aggregated payment data are not readily available. We analyzed the extent and distribution of industry payments to the executive board members of professional medical associations in Japan.
Methods | We selected 19 major medical associations, 1 for each of the basic clinical medical fields, as categorized by the Japanese Medical Specialty Board. For 2016, we collected data on payments (fees for speaking, writing, and consulting) made to executive board members of these 19 associations from all 71 pharmaceutical companies belonging to the Japan Pharmaceutical Manufacturers Association. We obtained each company's data individually through their websites and integrated the data into a single database. We then summed the payments made to each of 405 executive board members. We converted Japanese yen to US dollars using the exchange rate of ¥112 per $1 on September 21, 2018. We also reviewed the websites of the 19 medical associations to determine if the associations disclosed the payments to their executive board members to the public.
Results | Of 405 executive board members, 352 (86.9%) received pharmaceutical company payments (Table) . The total amount paid was $6 468 585: $5 279 312 for speaking, $412 900 for writing, and $776 373 for consulting. The median payment was $7486 (interquartile range [IQR] , $1767-$20 277). Of the payments, $2 960 928 (45.8%) went to the 40 executive board members who received the largest payments; 12 were on the board of the Japanese Society of Internal Medicine, 7 on the board of the Japanese Urological Association, and another 7 on the board of the Japanese Dermatological Association. The highest median payment was to the executive board members of the Japanese Society of Internal Medicine ($51 974; IQR, $33 900-$86 349). Payments to board members of the Japanese Society of Internal Medicine accounted for 20.8% of the total payments, followed by the Japanese Urological Association (14.9%) and the Japanese Dermatological Association (11.1%). We found no evidence that any of the 19 associations publicly disclosed the pharmaceutical company payments to their executive board members.
Discussion | In 2016, most of the executive board members of the 19 leading professional medical associations in Japan received payments from pharmaceutical companies, primarily for speaking and consulting. Executive board members of 3 medical associations-internal medicine, urology, and dermaLetters tology-accounted for 46.8% of all the payments. We found no evidence that any of these payments were publicly disclosed. The payments, as well as the lack of disclosure by the medical associations themselves, raise concerns about the potential influence of payments on professional activities. Limitations of our study include possible inaccuracies in the payment information and the limited types of payments that were analyzed. Information about research funding, donations, meals, and other gifts was not available. Medical device companies were not included because their payments are not sufficiently disclosed.
It has been argued that no executive board members of professional medical associations should receive industry payments.
1 Although this may remain an aspirational goal, it would be desirable if there were fewer and smaller payments and if all such payments were publicly disclosed by the associations themselves on their websites. 
Assessing the Use of Google Translate for Spanish and Chinese Translations of Emergency Department Discharge Instructions
Patients with limited English proficiency experience communication barriers to health care in English-speaking countries. Written communication improves comprehension, 1 but pretranslated standard instructions cannot address patientspecific issues (eg, medication titration). Machine translation tools, including Google Translate (GT), have potential to improve communication with these patients, but prior studies showed limited accuracy; 1 study found that GT Spanish translations of patient education materials were 60% accurate, with 4% resulting in serious error.
2
In 2017, GT changed its translation algorithm, claiming significant improvement.
3 In this study, we assess the use of GT to translate emergency department (ED) discharge instructions into Spanish and Chinese.
Methods | We abstracted 100 free-texted ED discharge instructions and oversampled for medication changes and common complaints. 4 We analyzed each sentence by content category; The primary outcome was sentence translation accuracy, assessed for overall content accuracy, not word-for-word accuracy, and coded as a binary outcome. Two clinicians coded accuracy independently; a third adjudicated disagreements. A second translator reviewed back-translations deemed inaccurate to ensure these were not back-translator error.
Potential for harm from inaccurate translations was assessed by 2 clinicians (with a third adjudicating) using an established rating system: clinically nonsignificant, clinically significant, and life-threatening potential harm.
6 For analyses, we used a binary variable (clinically significant/lifethreatening vs clinically nonsignificant/no harm). We used logistic regression analyses stratified by language to assess associations between sentence characteristics and accuracy and/or harm. Variables with significance of P < .20 in bivariate analyses were used in multivariable analyses.
Results | The 100 sets of patient instructions contained 647 sentences. Overall, 594 (92%) and 522 (81%) sentences were accurately translated into Spanish and Chinese, respectively, by GT ( Table 1) . A minority of inaccurate translations had potential for clinically significant harm: in Spanish, 15 (28%) of 53 inaccuracies and 15 (2%) of 647 sentences; in Chinese, 50 (40%) of 125 inaccuracies and 50 (8%) of 647 sentences. Some errors were correct translations of errant English instructions, but overall, content was inaccurate owing to grammar or typographical errors ( Table 2 ) that would readily have been overlooked or understood by a reader of the English text.
Only spelling and grammar anomalies were associated with inaccurate translations in multivariable analyses: Spanish (odds ratio [OR], 2.6; 95% CI, 1.1-5.8); Chinese (OR, 2.6; 95% CI, 1.3-5.0).
In multivariable analyses, potential harm was associated in Spanish with a Flesch-Kincaid reading level higher than eighth grade (OR, 4.0; 95% CI, 1.2-13.5) and follow-up instructions (OR, 3.5; 95% CI, 1.2-10.2); and in Chinese with medical terminology (OR, 2.4; 95% CI, 1.2-4.9), spelling or grammar anomalies (OR, 3.1; 95% CI, 1.4-7.2), and colloquial English (OR, 5.9; 95% CI, 1.4-24.7).
